Burrill Conferences

Sponsors

Gold SponsorSilverBronzeEvent Partners

Life Sciences Conferences

The Burrill Personalized Medicine Meeting

Featured Speakers

G. Steven Burrill
Chief Executive Officer
Burrill & Company

One Embarcadero Center
Suite 2700
San Francisco, CA 94111
(415) 591-5400
www.burrillandco.com

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Boards of Pharmasset (NASDAQ: VRUS) and BioImagene, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Intranasal, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50).

In addition to his work with leading life science companies, Mr. Burrill is a founder and currently serves as the Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the Board of the Campaign for Medical Research as well as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Other not-for-profit activities include serving on the Boards of Directors of the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute (Emeritus), The Exploratorium, The Kellogg Center for Biotechnology, the University of Maryland Biotechnology Institute, the MIT Center for Biomedical Innovation, Kramden Institute, and the National Health Museum. He also serves on the Purdue Discovery Park External Advisory Committee as well as the editorial board of the Journal of Commercial Biotechnology and serves as an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin—College of Agriculture and Life Sciences, Carnegie Mellon, and Duke University, and is an adjunct professor at University of California, San Francisco.


Caroline A. Kovac, PhD
Managing Director
Burrill & Company

One Embarcadero Center
Suite 2700
San Francisco, CA 94111
(415) 591-5400
www.burrillandco.com

Dr. Kovac joined Burrill & Company after retiring from IBM, where she was responsible for the strategic direction of IBM's global healthcare and life sciences business. She led a team in developing the latest information technology solutions and services, establishing partnerships and overseeing IBM investment within the healthcare, pharmaceutical and life sciences markets. In more than 20 years at IBM, Dr. Kovac held a number of executive management positions, including vice president at IBM Research, where she was instrumental in launching the Computational Biology Center and the massive Blue Gene supercomputer project. Starting with only two employees as an emerging business unit in the year 2000, Dr. Kovac successfully grew IBM's life sciences business unit into a multi-billion dollar business, and one of IBM's most successful ventures to date with more than 1500 employees worldwide.

Her main focus at Burrill is developing and executing investment strategies for leading edge technologies that are contributing to the transformation of medicine and healthcare including: personalized medicine, the use of IT in healthcare, stem cell research, medical devices and diagnostics, and bio-nanotechnology. In addition, she works as part of the Burrill International Group team building the company's life science focus on emerging economies such as China, India, Malaysia and the Middle East.


Eric J. Topol, M.D.
Chief Academic Officer, Scripps Health; Director, Scripps Translational Science Institute (STSI)
Scripps Health

3344 North Torrey Pines Court
La Jolla, CA 92037
(858)554-5708
www.stsiweb.org

Eric J. Topol, M.D. is the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award (CTSA) Consortium. He is Professor of Translational Genomics at The Scripps Research Institute, the Chief Academic Officer of Scripps Health, and a Senior Consultant cardiologist practitioner at Scripps Clinic.
Prior to coming to Scripps, he served on the faculty of Case Western as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and raised its status to rank #1 by US News and World Report for 11 consecutive years, and founded the Cleveland Clinic Lerner College of Medicine. His work in the genomics of heart attack has led to discovery of key genes (MEF2A deletion, THSB-4 variant) which led to recognition by the American Heart Association top 10 research advances in 2002 and 2004. As a leader in clinical trials of novel therapeutics, he administered recombinant t-PA to the first patient in 1984, pioneered and led the clinical development of clopidogrel (Plavix),  bivalirudin (Angiomax), and abciximab (ReoPro). He has over 1000 original peer reviewed publications, and has edited over 30 books, including the Textbook of Interventional Cardiology (5th ed), and the Textbook of Cardiovascular Medicine (3rd ed).  Dr. Topol has been elected to the Institute of Medicine of the National Academy of Sciences, the American Association of Physicians and recognized by the Institute of Scientific Information (ISI) to be in the top 10 cited biomedical researchers in medicine in the past decade. 




Susan Desmond-Hellmann, MD, MPH
President, Product Development
Genentech

www.gene.com

Susan Desmond-HellmannSusan Desmond-Hellmann is president, Product Development.  In this role, Hellmann is responsible for Genentech's Development, Process Research & Development, Business Development, Product Portfolio Management, Alliance Management and Pipeline Planning Support functions. Hellmann is a member of Genentech’s executive committee.

Hellmann joined Genentech in 1995 as a clinical scientist, and she was named chief medical officer in 1996. In 1999, Hellmann was named executive vice president, Development and Product Operations. In addition to her work at Genentech, Hellmann is an adjunct associate professor at the University of California, San Francisco (UCSF). Hellmann is board-certified in Internal Medicine and Medical Oncology and completed her clinical training at UCSF. In March 2004, Hellmann was named to her current role as president, Product Development.

Prior to joining Genentech, Hellmann was associate director of clinical cancer research at Bristol-Myers Squibb’s Pharmaceutical Research Institute. While at Bristol-Myers Squibb, she was the project team leader for Taxol.

Hellmann has also served as assistant professor, Hematology-Oncology at UCSF. During her nine years of training in internal medicine and oncology, Hellmann spent two years as visiting faculty studying AIDS and cancer at the Uganda Cancer Institute. She also spent two years in private practice before returning to clinical research.

In July 2008, Hellmann was appointed to the California Academy of Sciences Board of Trustees. She was named to the Biotech Hall of Fame in 2007 and as Healthcare Businesswomen’s Association’s “Woman of the Year” for 2006. Hellmann was named to FORTUNE magazine’s 2007, 2006, 2005, 2004, 2003 and 2001 “Top 50 Most Powerful Women in Business” list. In 2006, 2005 and 2004, The Wall Street Journal listed Hellmann as one of its “Women To Watch.” From 2005-08, Hellmann served as member of the American Association for Cancer Research Board of Directors, and in 2001 she was named to the board of directors of the Biotechnology Industry Organization.  Hellmann serves on the corporate board of Affymetrix.

Hellmann received her Bachelor of Science in pre-medicine and her medical degree from the University of Nevada, Reno. She also holds a Master of Public Health degree from the University of California, Berkeley.




Dean Sproles
CEO
Inverson Genetics Diagnostics

19805 North Creek Parkway
Bothell,WA 98011
www.iversongenetics.com

Dean Sproles, age 31, is the Founder, President, Chief Executive Officer, and Chairman of the Board for Iverson Genetic Diagnostics, Inc.  Mr. Sproles is an entrepreneur and scientist specializing in gene expression and protein sequencing.  He is the innovator of the Company’s genetic diagnostic technology.  An alumnus of the Citadel, Mr. Sproles graduated magna cum laude in the Honors Program earning a B.S. in Biology.  Having dedicated his research to proteomics, genomics, and DNA / RNA analysis, Mr. Sproles has over ten years of laboratory experience including extensive experience managing privately funded research laboratories.  Most recently Mr. Sproles served as a product development consultant at the privately funded Meridian Valley Laboratory in Renton, Washington.  His most recent publications reflect his involvement in the creation and implementation of global standards in genetic research




William D. Young
Chairman of the Board & CEO
Monogram Biosciences

345 Oyster Point Blvd.
South San Francisco, CA 94080-1913
(650) 635-1100
www.monogrambio.com

William D. Young is Chairman of the Board and Chief Executive Officer of Monogram Biosciences, a leader in developing and commercializing innovative products to help guide and improve the treatment of HIV and cancer. From March 1997 to October 1999, Mr. Young was Chief Operating Officer at Genentech, Inc., a biotechnology company. As COO at Genentech, Mr. Young was responsible for all of the company's development, operations and commercial functions. Mr. Young joined Genentech in 1980 as Director of Manufacturing and Process Sciences and held various executive positions prior to becoming COO. Prior to joining Genentech, Mr. Young was employed by Eli Lilly and Company for 14 years. Mr. Young is a member of the board of directors of Biogen IDEC and Theravance, Inc. He received his bachelor's degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology.




Asif Dhar, MD, MBA
Senior Manager
Deloitte Consulting LLP

555 12th St. N.W.
Suite 500
Washington, District Of Columbia 20004-1207
www.deloitte.com

Dr. Asif Dhar is a Senior Manager in the Federal Health practice of Deloitte Consulting.  He specializes in helping clients develop innovative health care operations and technology strategies to improve clinical outcomes and therapeutic discovery.

Dr. Dhar brings deep functional and management experience that spans public and private sector clients.   He has provided senior leadership to numerous Electronic Health Record (EHR) implementations in the US, Canada, and the UK.  He has also helped develop multiple enterprise data warehousing solutions, clinical discovery applications, and quality improvement programs at large integrated delivery networks and academic medical institutions. 

Most recently, Dr. Dhar has developed new health and clinical trial management strategies for large Federal government clients.   His Federal experience includes:
• Biomedical Informatics advisory services for the National Institutes of Health (NIH),   Food and Drug Administration (FDA), and the Department of Veterans Affairs (VA)
• Functional testing advisory services for the Department of Defense (DoD) Clinical Information Technology Program Office
• Global cancer clinical trial database development for the NIH National Cancer Institute (NCI)
• EHR Special Emphasis Panel member for the NIH National Human Genome Research Institute (NHGRI)

Prior to joining Deloitte Consulting, he served as a management consultant with Booz Allen Hamilton, as a physician executive with the Cerner Corporation, and as a clinical outcomes researcher with the University of Chicago Department of Medicine.

Dr. Dhar holds a Medical Degree from the University of Illinois, a Masters in Business Administration degree from the University of Chicago Graduate School of Business, and a Bachelor in Arts degree from the University of Chicago.  





Mari Baker
President & CEO
Navigenics

One Lagoon Drive, Suite 450
Redwood Shores, CA 94065
(650) 585-7700
www.navigenics.com

Mari Baker is President and Chief Executive Officer of Navigenics, a company that educates and empowers consumers with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Ms. Baker was most recently an executive-in-residence at Kleiner Perkins Caufield & Byers, which she joined in 2006. Prior to that, she was president of BabyCenter, LLC, a Johnson & Johnson company. Under her leadership, BabyCenter became the world's leading Web site for new and expectant parents, winning numerous online health awards and expanding significantly offline and internationally.

Prior to her tenure with BabyCenter and Johnson & Johnson, she was a senior vice president at Intuit, Inc., which she joined in 1989 as product manager for Quicken. Ms. Baker led the growth of Quicken into the No. 1 personal finance product in the world, along with international expansion and the launch of Quicken.com. Ms. Baker also held executive or product management positions at Now Software, Migent Software and E.F. Hutton.

Ms. Baker attended Stanford University, graduating with degrees in economics and sociology. She served on the board of trustees of Stanford University from 1996 to 2003, including oversight of the Stanford Medical Center, and continues to serve as a trustee emeritus. She currently serves on the board of directors of the Cozi Group and is a member of the Young Presidents' Organization.




LTC(P) Alexander Stojadinovic, MD
Vice Chairman, Department Surgery, Walter Reed Army Medical Center; Program Leader, Gastrointestinal Cancer Program, United States Military Cancer Institute

LTC(P) Alexander Stojadinovic is a distinguished military graduate of the United States Military Academy, and received a Doctor of Medicine degree from Uniformed Services University of the Health Sciences. He is a graduate of the Walter Reed Army Medical Center General Surgery Residency and has served as General Surgeon, DeWitt Army Community Hospital from 1997-1999. He completed a two-year fellowship in Surgical Oncology at Memorial Sloan Kettering Cancer Center in 2001. LTC(P) Stojadinovic has been an Attending Surgeon at Walter Reed Army Medical Center since that time. He deployed to Iraq as a Forward Surgeon in support of Operation Iraqi Freedom with the 2nd Armored Cavalry Regiment FST from 2003-2004.  He has served as Vice Chairman and Principal Investigator for the Department Surgery at Walter Reed Army Medical Center for the past two years as well as Program Leader, Gastrointestinal Cancer Program, United States Military Cancer Institute. He is an Associate Professor of Surgery at the Uniformed Services University of the Health Sciences and the recipient of the United States Army Surgeon General’s “A” Proficiency Designator for academic excellence, and the U.S. Army Medical Department Regiment’s Order of Military Medical Merit. His Military awards and decorations include the Bronze Star Medal, Combat Medical Badge, Army Commendation Medal – Valor, Air Assault Badge and Parachute Badge.  LTC(P) Stojadinovic is the first of two children of George and Julie Stojadinovic, who currently reside in San Diego, California. LTC(P) Stojadinovic and his wife Tanja have one son, Nicholas, age 5, who is his parents’ greatest blessing and joy.
 




Franklyn G. Prendergast, MD, PhD
Director, Center for Individualized Medicine Research
Mayo Clinic

200 First St. S.W.
Rochester, MN 55905
www.mayo.edu

Dr. Prendergast obtained his medical degree with honors from the University of the West Indies in 1968.  After internship, he attended Oxford University in England as a Rhodes Scholar where he obtained his bachelors and masters degree in Physiology.  Thereafter, he was a resident in Internal Medicine at Mayo Clinic and then obtained a PhD degree in Biochemistry from the University of Minnesota in 1977.  He joined the Mayo staff as a consultant and assistant professor in the Department of Pharmacology in 1978.  Over the years he rose through the academic ranks at Mayo Clinic to become Professor of Pharmacology and of Biochemistry and Molecular Biology in 1986.  He became the Edmond and Marion Guggenheim Professor in these same subjects in 1988. His principal areas of research have long been protein chemistry and biophysics.  He has published in excess of 300 abstracts and papers.  Currently, he holds a strong interest in drug design and discovery and computational biology.

Administratively, Dr. Prendergast has held many responsibilities within Mayo Clinic.  Foremost among these are his appointments as Chair of the Department of Biochemistry and Molecular Biology, 1986-1989 inclusive; Director for Research Mayo Clinic Rochester, 1989-1992 inclusive; Mayo Clinic Rochester Board of Governors, 1989-1996 inclusive; Board of Directors, St. Marys Hospital and Methodist Hospital Rochester and Mayo Foundation Executive Committee (now called Mayo Clinic Board of Governors) 1999-2006 inclusive.  He has served continuously as a member of the Mayo Board of Trustees from 1990-present.  From 1994-2006 inclusive he was the Director of the Mayo Clinic Cancer Center.  In November 2006 he assumed the responsibility as Director for the newly created Mayo Clinic Center for Individualized Medicine, the post he holds today.

Extramurally, Dr. Prendergast has served the National Institute of Health extensively over the last 20 years beginning with roles on sundry study sections and other grant review committees, then on innumerable advisory groups most notably Division of Research Grants as a charter member of the Board of Advisors, National Advisory General Medical Sciences Council, Board of Scientific Advisors for the National Cancer Institute, and currently as a member of the National Cancer Advisory Board.  He has also served as a member of special review committees for the Institute of Medicine, National Research Council.  Currently Dr. Prendergast is a member of the Board of Directors of Eli Lilly, Cellumen, the Infectious Disease Research Institute, Hamm Clinic and the Board of Reagents of St. Olaf College. 




Bruce Quinn, MD, PhD
Senior Health Policy Specialist & Former California Medical Director, NHIC
Foley Hoag

www.foleyhoag.com

Bruce Quinn, M.D., Ph.D., formerly the Contractor Medical Director for the California Medicare Part B program, is a senior policy strategist within the firm’s Government Strategies practice, where he focuses on Medicare coverage and payment matters for new technologies.

Bruce is a national leader in the areas of Medicare coverage and payment, claims and billing, and Medicare contractor reform processes.  Dr. Quinn works with companies, providers and venture capital investors to develop strategies for Medicare payment for new technologies.  A large part of this work is on local and national coverage decisions.  Bruce focuses, in particular, in the emerging field of personalized medicine and molecular diagnostics.  He also advises clients on Medicare Administrative Contractor (MAC) reform and its effect on payment policy.

Before managing the Medicare Part B program, Bruce was a physician executive in the Health & Life Sciences division of Accenture, a global consulting organization, and a physician-scientist at Northwestern University, leading pathology research for Northwestern’s NIH-funded Alzheimer Research Center.  He also held academic positions at the NYU School of Meidcine and UCLA Center for Health Sciences.  

Foley Hoag LLP is a leading national law firm in the areas of dispute resolution, intellectual property, and corporate transactions for emerging, middle-market, and large-cap companies. With a deep understanding of clients’ strategic priorities, operational imperatives, and marketplace realities, the firm helps companies in the biopharma, high technology, energy technology, financial services and manufacturing sectors gain competitive advantage.  For more information visit www.foleyhoag.com.

 




Randy Scott, PhD
Chairman & CEO
Genomic Health

301 Penobscot Drive
Redwood City, CA 94063
(650) 556-9300
www.genomichealth.com

Randy Scott, Ph.D. is the co-founder, Chairman, and Chief Executive Officer of Genomic Health. Dr Scott brings more than 18 years of experience to Genomic Health and has a strong history of scientific innovation.  In addition to founding Genomic Health, Dr Scott co-founded Incyte, one of the worlds’ first genomic information business.  An inventor on 25 issued patents, Dr. Scott has authored numerous scientific publications in the fields of protein biology, gene discovery, and cancer.  In 1997, NASDAQ and Ernst & Young recognized him as Silicon Valley Entrepreneur of the Year for life sciences.  Dr. Scott received a bachelor's degree in chemistry from Emporia State University in Emporia, Kansas.  In 1983, he earned a Ph.D. in biochemistry from the University of Kansas, where he conducted studies in protease biology.




Matthew Hudes
National Managing Principal
Deloitte Consulting

50 Fremont Street
San Francisco, CA 94105
www.deloitte.com

Matthew Hudes is U.S. Managing Principal, Biotechnology, for Deloitte’s Life Sciences & Health Care Industry practice.  In this role, he develops, provides and leads the practice’s professional services, working with Tax, Audit, Consulting, and Financial Advisory Services, for this dynamic industry sector.  Previously, he was the Chairman and CEO of Accélère, a software company that developed a system to find patients (and investigators) for clinical trials and to improve researchers’ access to information typically “trapped” in laboratory and medical systems.
Matthew has provided strategic professional services to leading biotechnology and pharmaceutical companies, including Amgen, Amylin, Biogen Idec, Chiron, Genentech, Gilead, Johnson & Johnson, and Sanofi-Aventis.  He speaks frequently about topics such as the use of technology for innovating clinical research, manufacturing and quality, regulatory compliance, and supply chain.
Formerly, Matthew led the global Capgemini Life Sciences Biotechnology and R&D practice.  As a former Partner and practice leader with Ernst & Young LLP, he acted as a strategic advisor to leading-edge companies in life sciences and high technology over a period of 17 years.  Matthew was a founding management team member of three start-up companies, one of which had a successful IPO and was subsequently acquired. The other two were successfully acquired by larger companies.


Education:
B.A., Psychology, University of Connecticut, Storrs, CT

MBA, Santa Clara University, Santa Clara, CA -- Concentration in Operations & Management Information Systems

Professional Affiliations:
• American Production and Inventory Control Society

Publications:
• Quoted in “Billion Dollar Babies – Biotech Drugs and Blockbusters,” Nature Biotechnology, April 2007
• Quoted in “The Age of Personalized Medicine,” PharmaVOICE, February 2007




Michael F. Christman, Ph.D
President & Chief Executive Officer
Coriell Institute for Medical Research

403 Haddon Avenue
Camden, NJ  08103
www.coriell.org

Michael F. Christman, Ph.D. was appointed as President and Chief Executive Officer of the Coriell Institute for Medical Research, effective June 1, 2007.  In the last year he has  initiated the Coriell Personalized Medicine Collaborative, a major research study designed to take an evidence-based approach to determining the utility of using genome information in the clinic.

Dr. Christman is an expert in genetics and genomics and most recently served as professor and founding chair of the Department of Genetics and Genomics for Boston University School of Medicine.  He has also served as associate professor, Department of Microbiology, University of Virginia; assistant professor, University of California at San Francisco, Department of Radiation Oncology; and was a Jane Coffin Childs postdoctoral fellow at M.I.T.

Dr. Christman received his bachelor’s degree in chemistry with honors from the University of North Carolina, Chapel Hill in 1981 and a doctorate in biochemistry from the University of California, Berkeley in 1985.




Kathryn Lowell
Deputy Secretary for Health Systems and Life Sciences
Business, Transportation and Housing Agency

980 9th Street
Sacramento, CA 95814
www.bth.ca.gov

Appointed by Governor Schwarzenegger and the Secretary to develop and execute policy and strategic initiatives to grow the California-based health and life science market.  Kathryn serves as an Administration point person for the Life Sciences industry. She provides regulatory & policy oversight and guidance to the Department of Managed Health Care and the Office of the Patient Advocate as well.  Kathryn also serves as the Agency’s health care information technology point person.  She recently co-led efforts for a Commission study on the Financing of health care information technology.  Kathryn is a Board Member of the California Privacy and Security Advisory Board and a Board Member of the California Telehealth Network Advisory Council.

Prior to her current position, Kathryn was the Vice President for Strategic Growth at Lumetra, a health care consulting firm, and Vice President of Maximus (NYSE:MMS) which is a national IT and government services consulting firm.  Prior to her consulting work, Kathryn was Assistant Secretary for Health at the California Health and Human Services Agency.  At that time, she helped to create and staff the Biotechnology Council for the State of California.  In her early years, she worked as a legislative analyst for a Congressman on the House Ways and Means Committee. 

Kathryn is a graduate of Stanford University.  She received her Master’s Degree in Public Policy from USC, under academic scholarship.  She attended Harvard University’s Program for Senior Executives in State Service at the JFK School under a career scholarship award. 




Steven A. R. Murphy, MD
President
Helix Health

969 Park Avenue
New York, NY 10028
(888) 584-8999
www.helixhealth.org

Steven A.R. Murphy, M.D. is a physician, educator and entrepreneur, influential in diverse fields from education and health care to software development and the blogosphere.

Dr. Murphy is the Founder and President of Helix Health, a company dedicated to the delivery of personalized genomic health care through physicians.  Acting as the managing partner for Helix Health's flagship personalized medical practices in New York City and Greenwich, Connecticut, Dr. Murphy and his colleagues determine best practices in the care of patients with genetic predisposition to disease.

Currently he serves on the faculty at New York Medical College as an Instructor in the Department of Cell Biology and Anatomy. Dr. Murphy is a prominent blogger in the field of personalized medicine and genomics and is a consultant to several venture capital firms. In addition, he is a member of the Informed Cohort Oversight Board of the Coriell Personalized Medicine Collaborative.

Dr. Murphy received two undergraduate degrees from the Pennsylvania State University where he studied genetics and religion. He went on to receive a medical degree from the New York Medical College, pursuing externships in medical genetics at Yale University, Albert Einstein College of Medicine, and the Mount Sinai School of Medicine during his medical school training. Dr. Murphy completed an internship in pediatrics and medical genetics at the Mount Sinai School of Medicine and trained in Internal Medicine at Yale New Haven Health’s Greenwich Hospital.

Concurrently while managing Helix Health, Dr. Murphy serves as Clinical Fellow in the Department of Genetics at Yale School of Medicine where he studies education and its influence on the provision of genomic medical care.

 




Michael S. Paul, Ph.D.
President & Cheif Executive Officer
LineaGen, Inc.

423 Wakara Way, Suite 200
Salt Lake City, UT  84108
(801)931-6200
www.lineagen.com

Michael S. Paul, Ph.D., is the President and CEO of LineaGen, Inc., a biotechnology company focused on the discovery and commercialization of biomarker-based molecular diagnostics for the improved diagnosis and treatment of common diseases.  Dr. Paul also works closely with vSpring Capital and Mesa Verde Venture Partners as a Venture Partner in the evaluation of life science investment opportunities.  Prior to founding LineaGen, Inc., he was the Chief Operating Officer and President at LineaGen Research Corporation, a Utah non-profit organization from which LineaGen, Inc. was founded.  Prior to LineaGen, Dr. Paul worked for Huntsman Biotechnology Corporation as Vice President of Business Development, and for the publicly-traded biopharmaceutical company, NPS Pharmaceuticals as Director of Strategic Development.  Dr. Paul serves on the Board of Trustees for the Utah Technology Council (UTC), serves as Chair of UTC’s Life Science Advisory Board, and was an Appointee of the Governor of Utah to the Steering Committee for the Utah Technology Industry Commission. Dr. Paul has also worked at the University of Utah Technology Transfer Office in the marketing of University inventions to the pharmaceutical and biotechnology industries.  Dr. Paul is a licensed patent agent of the United States Patent and Trademark Office and received his B.A. in Biology from Colby College and his Ph.D. in Biochemistry and Molecular Biology from the University of Utah.  Dr. Paul most recently served as the co-chair for the first annual National Personalized Healthcare Summit held in Utah in October 2008.




William Welch
SVP & Chief Commercial Officer
Monogram Biosciences

345 Oyster Point Blvd.
South San Francisco, CA 94080-1913
(650) 635-1100
www.MonogramBio.com

William J. Welch has served as Monogram Biosciences' Senior Vice President and Chief Commercial Officer since September 2005. From 1998 to 1999 and from 2001 to August 2005, Mr. Welch was with LaJolla Pharmaceutical, Inc., most recently as Vice President, Sales & Marketing. From 1999 to 2001, Mr. Welch was Vice President of Global Marketing for Dade Behring MicroScan where he managed marketing and strategic development for a $150 million business. From 1993 to 1998, Mr. Welch held a number of management positions with Abbott Laboratories, including General Manager of the Ambulatory Infusion Systems Division. Mr. Welch holds a BS from the University of California at Berkeley and an MBA from Harvard University




Dr. Kathy Behrens
Member
President’s Council of Advisors on Science and Technolgy

Dr. Behrens presently serves as a member of the President’s Council of Advisors on Science and Technology (PCAST), a role in which she has served since 2001.  She was a director of the Board on Science, Technology and Ecominic Policy (STEP) for the National Research Council from 1997-2005, at which time she participated as a member of the Institute of Medicine Committee on New Approaches to Early Dectection and Diagnosis of Breast Cancer.  Kathy was a director of the National Venture Capital Association from 1993 to 2000, also serving as President of the NVCA from May, 1998 through April, 1999, Chairman from May 1999 through September, 1999, and Past Chairman from October 1999 through April, 2000.  Dr. Behrens was a Trustee of the University of Californian, Davis, Foundation from 1996-2001 and currently is a member of the Advisory Committee for the J. David Gladstone Institute.  Kathy holds a Ph.D. in Microbiology from the University of California, Davis.

Kathy established a career in the financial services industry, working with Robertson Stephens & Co. from 1993 through 1996,  at which time the firm was sold.  During this tenure, she became a general partner and managing director.  Dr. Behrens continued in her capacity as a General Partner for selected venture funds for RS Investments from 1996 through today, after management led a buy-out of that firm from Bank of America.  Her professional career included tenures as a public-market biotechnology securities analyst, as well as venture capitalist focusing on healthcare, technology and related investments.  She was intstrumental in the founding of several biotechnology companies including Protein Design Labs, Inc. and COR Therapeutics, Inc. and participated in financing a broad range of biotechnology, health services and device companies.  Most recently, Kathy served as a director of Abgenx, Inc.  Inc a role that spanned that firm’s early rounds of private financing through the company’s sale in 2006 to Amgen, Inc.  Dr. Behrens is continuing to wind-down venture funds on behalf of RS Investments as a General Partner of RS&Co. Venture Partners IV, L.P.




John Sninsky, Ph.D
Vice President of Discovery Research
Celera

1401 Harbor Bay Parkway
Alameda, CA 94502
www.celera.com


John Sninsky, Ph.D is the Vice President of Discovery Research at Celera. The Discovery Research group encompasses teams of scientists who work in: specific disease areas, a high-throughput genotyping and expression facility, statistical genetics, biomarker development, computational biology and future diagnostic technologies.  His primary focus is the application of genetic and genomic tools to identify and develop diagnostic and pharmacogenomic assays for common complex disease and cancer. He is the author of numerous scientific papers including methods in molecular biology, application of the polymerase chain reaction (PCR) to virology and more recently genome-wide genetic disease association studies. Cardiovascular and liver disease as well as breast cancer has been the focus.

Dr. Sninsky received a bachelor’s degree in biology from Bates College (1972) and a Ph.D. in biology from Purdue University (1976).  He was a postdoctoral fellow in Genetics and Medicine at Stanford University School of Medicine (1977-81). From 1981 to 1984, Dr. Sninsky was on the faculty at Albert Einstein College of Medicine (AECOM) in the Department of Microbiology and Immunology with a joint appointment in the Department of Molecular Biology. He was a member of the AECOM Liver and Cancer Centers. From 1984 to 1991, he worked at Cetus Corporation where he was responsible for the immunoassay and molecular diagnostics programs. 

From 1991 to 1998, John was the Senior Director of Research at Roche Molecular Systems.  His team of scientists devised PCR diagnostic assays for many infectious pathogens as well as for genetic diseases and cancer. In 1998, he was promoted to Vice President, Discovery Research as well as Vice President, Roche Genetics, an initiative that coordinated the genetic and genomic efforts between the pharmaceutical and diagnostics divisions.  Dr. Sninsky joined Celera in 2001.




Robert Monroe, MD, PhD,
Chief Medical Officer
BioImagene, Inc.

1601 S. De Anza Blvd., Suite 212
Cupertino, CA 95014
www.bioimagene.com

Robert Monroe, MD, PhD, is the Chief Medical Officer of BioImagene, Inc., a leading provider of total imaging solutions for pathologists, researchers and drug developers in clinical diagnostics and life sciences.  Dr. Monroe leads the company’s efforts to develop innovative tools for pathologists to arrive at more accurate, quantitative, and reproducible diagnoses.  As the head of clinical and regulatory affairs, Dr. Monroe also oversees FDA studies of imaging hardware and software designed to help pathologists interpret various studies.  The results of many of these studies are used by oncologists and other physicians to “personalize” therapy for cancer patients.  Prior to joining BioImagene, Dr. Monroe practiced pathology for several years, most recently with Central Coast Pathology Consultants, where he led cytopathology and molecular pathology programs. During his tenure with Central Coast Pathology, he served as the Co-Director of Pathology at Marian Medical Center in Santa Maria, California. Dr. Monroe is board certified by the American Board of Pathology in cytopathology, anatomic pathology and clinical pathology. He received his degrees in medicine and genetics from Harvard Medical School, where he conducted pioneering research on immune system development with Dr. Frederick Alt.  Dr. Monroe completed residency and fellowship training in pathology and cytopathology at Stanford University and the UCLA Medical Center. 




Robert Wells
Partner
HealthFutures, LLC

600 Maryland Avenue, NW
Suite 835W
Washington, DC 20024
www.healthfutures.com

Robert Wells has more than twenty years experience in government relations, pubic policy and international corporate development. His diverse career has given him expertise in business and policy issues associated with life sciences, health care, financial services and global markets.

Prior to co-founding HealthFutures, Robert served for seven years with Affymetrix, Inc, the world leader in microarray technology, as Vice President for Corporate Affairs and International Markets. In that role, he directed the company’s internationally respected government relations program, believed by many to be the most forward thinking in the life sciences and health care industry. Robert sought not only to represent the company’s commercial and regulatory interests, but to open a wider dialogue with the patients, payers, researchers, clinicians, ethicists, legal experts, investors and other stake holders in the modern healthcare ecosystem.

Robert is a founding member of the Personalized Medicine Coalition; he also played an industry role in the effort to enact greater federal privacy protection for genetic information and drove an international dialogue on innovative intellectual property regimes. Working in corporate development, he launched a successful business strategy to enter the China market and started innovative collaborations with world class research centers in Sweden, France, Singapore and Korea.

Before joining Affymetrix, Robert had a highly successful career with Citigroup where he served as Vice President for International Government Relations, coordinating pubic policy efforts in the company’s almost-100 overseas offices. He has also taken time from his traditional career path to work in three presidential campaigns and to write two television pilots for Columbia/Tri-Star Television.

Robert completed his undergraduate work at the University of North Carolina / Chapel Hill. He also holds a JD degree from the Wake Forest University School of Law. He is a member of the Board of Directors of the Personalized Medicine Coalition and chairs the organization’s Public Policy Committee. He has been a frequent speaker before various professional groups.

 

 




William Wachsman, MD, PhD
Associate Professor of Medicine in the Division of Hematology-Oncology
University of California, San Diego School of Medicine

9500 Gilman Drive, MC 0602
La Jolla, CA 92093-0602
http://som.ucsd.edu/

Dr. Wachsman is an Associate Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Diego School of Medicine and Staff Physician in the VA San Diego Healthcare System. His expertise is in the areas of microarray technology and biomarker discovery. Dr. Wachsman directs the Microarray Shared Resource and leads the AIDS-related Malignancy Specialized Cancer Unit at Moores Cancer Center at UCSD. He is also Associate Director of the GeneChip Core Laboratory and Staff Physician at the VA San Diego Healthcare System and Attending Medical Staff at UCSD Medical Center. Dr. Wachsman has received numerous fellowships and honors in the medical field and authored 60 publications as well as being named as inventor on two patents. Dr. Wachsman received his B.S., M.D. and Ph.D. degrees from Case Western Reserve University.

 




Jeffrey Trent, PhD
President & Scientific Director
Translational Genomics Research Institute (TGen)


445 N. Fifth St.
Phoenix, AZ  85004
www.tgen.org

Dr. Jeffrey M. Trent is President and Scientific Director of the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. TGen’s main goal as a non-profit medical research institute is focused on applying advances from the Human Genome Project to discover the molecular basis of disease, identifying factors contributing to disease progression and severity, and accelerating new drug development to advance clinical treatments for patients. TGen’s research focuses on a variety of diseases, including Alzheimer’s, autism, diabetes and multiple subtypes of cancer. TGen also engages in bio-defense research involving deadly pathogens, and has developed (under TGen’s world-recognized Physician-in-Chief, Dr. Daniel Von Hoff) a clinical research service in oncology, which annually touches the lives of hundreds of patients with cancer.

Prior to forming TGen in 2002, Dr. Trent served for 10 years as the Scientific Director of the National Human Genome Research Institute at the National Institutes of Health in Bethesda, Maryland. Under his guidance, NHGRI’s Division of Intramural Research became an internationally recognized research center in human genetics.

Dr. Trent’s research has provided important insights into the genetic basis of cancer. He is the author of more than 300 manuscripts in the scientific literature, numerous book chapters, invited reviews in the scientific literature, and hundreds of invited lectures. He has received numerous honors and awards, and has sat on the editorial boards of a dozen scientific publications. He specializes in developing and integrating novel “omic” technologies, supporting studies of molecular changes related to the predisposition to, and progression of, human cancers and other complex diseases.

Dr. Trent’s faculty positions include: The University of Arizona, where he was Deputy Director and Director for Basic Science of the Arizona Comprehensive Cancer Center; the University of Michigan, where he held the E. Maisel Endowed Professorship in Cancer Genetics, Professor of Human Genetics and Radiation Oncology, and Deputy Director and Director of Basic Research for the Michigan Comprehensive Cancer Center; and continuing Adjunct Professorships at Johns Hopkins University and at Arizona State University. He also is a Diplomat of the American College of Medical Genetics. And he is a Member of: the Mayo Clinic Comprehensive Cancer Center; the American Association for Cancer Research; the American Association for the Advancement of Science; the American Society of Human Genetics; and the American Society of Clinical Oncology.




Eugenia Garrett-Wackowski
Partner
Townsend and Townsend and Crew, LLP

2175 North California Boulevard
Walnut Creek, CA 94596
(925) 472-5000
www.townsend.com

Ms. Garrett-Wackowski’s practice focuses on various areas of intellectual property law associated with creating and maintaining intellectual property assets, particularly in the areas of chemistry and biotechnology. Working directly with in-house counsel and scientists at academic institutions, start-up biotechnology and drug discovery companies and large pharmaceutical companies, she has counseled clients and prepared and obtained patents in many technical areas, including organic chemistry, inorganic chemistry, biochemistry, molecular biology and immunology. Ms. Garrett-Wackowski regularly assists clients with patent portfolio management, U.S. and foreign patent prosecution, interference strategy, due diligence reviews, freedom to operate analyses, validity/infringement opinions and technology licensing.


EDUCATION
Santa Clara University, J.D., 1991
University of Notre Dame, M.S., 1990, Biotechnology and Chemistry
University of Notre Dame, B.A., 1986 Chemistry and Psychology
ADMISSIONS AND MEMBERSHIPS
State Bar of California, 1991
United States Patent and Trademark Office
Federal Court, Northern District of California
American Bar Association
American Chemical Society
San Francisco Bar Association
World Intellectual Property Trade Forum


PUBLICATIONS
“Ab Initio Molecular Orbital Calculations to Studies of Furanose Conformation and Dynamics,” Eugenia C. Garrett and Anthony S. Serianni, Computer Modeling of Carbohydrate Molecules, A.C.S. Symposium Series 430, American Chemical Society, Washington, D.C. 1990.




Paul Keckley, Ph.D.
Executive Director
Deloitte Center for Health Solutions

Washington, DC
www.deloitte.com

Paul H. Keckley, Ph.D., is Executive Director for the Deloitte Center for Health Solutions (“the Center”), a part of Deloitte LLP. He brings a distinguished 30 year career in health services research in the private sector and academic medicine. He is a health economist and policy expert, author, and much in demand speaker. The Deloitte Center for Health Solutions is an independent research organization focused on the issues and challenges of the US health system. Through proprietary research and trend analysis, it seeks to identify practical, innovative solutions that cut across traditional sectarian biases and structures. The Center’s research agenda includes trending of health care consumerism, monitoring of pay for performance programs, innovations in reducing the gap between evidence and practice, enhanced methods for information technology adoption, and models of community care coordination that improve population-based health status while reducing costs. Current studies include an analysis of state led health reforms, a 3000 household survey about health consumerism, evaluation of the medical home model, adoption trends for high deductible health savings accounts, the business case for personalized therapeutics, and an evaluation of health plans of major candidates for Presidential Campaign 2008. Recently released studies include Pay for Quality: A Strategic Perspective, Insurance for All: Catalyst for Health Reform and Coordinated Care through Health Information Exchanges.

Prior to joining Deloitte, Dr. Keckley served in several key roles at Vanderbilt University Medical Center’s senior management including oversight of domestic and international ventures, development of the integrative health program, development and implementation of evidence-based practice standards for use across the organizations’ acute and ambulatory operations, and
leadership of the economic analysis unit that supported a variety of the health services and life science initiatives. As Executive Director of the Vanderbilt Center for Evidence-based Medicine (VCEBM), a research center, he was principal investigator for several peer reviewed studies focused on the applications of evidence-based medicine in pay for performance and consumerism
models, and served on the editorial board of several leading health services research journals focused on quality and safety. He was Associate Professor in the Vanderbilt University School of Medicine, and Adjunct Professor of Health Management at the Owen Graduate School of Business’ health care MBA and MD-MBA programs.. Before joining Vanderbilt, Dr. Keckley served as Chairman of the Board of Interdent, a California dental practice management company; Chief Executive Officer of EBM Solutions, a developer of evidence-based guideline software founded by Vanderbilt,
Duke, Emory and Washington University-St. Louis; Chief Executive Officer of Aveta (formerly the IPA Management subsidiary of PhyCor Inc.), and Principal of The Keckley Group, a strategic planning consulting practice that served 1,200 U.S. provider organizations and health plans.

Dr. Keckley is an active member of the Health Executive Network, Healthcare Strategy Institute, Healthcare Leadership Council, Personalized Medicine Coalition, and others and serves on editorial boards of several national journals. He has authored three books and more than a dozen peer reviewed monographs in health services research journals. He has been profiled by ABC’s 20/20, CBS’s 60 Minutes, Fox News, CNN, The Wall Street Journal, and has been a keynote speaker at national industry meetings for the American College of Health Executives, American Medical Association House of Delegates, America’s Health Insurance Plans, the Personalized Medicine Coalition, E Health Initiative, American Hospital Association, National Quality Forum and others. Dr. Keckley has also testified for state Medicaid Review Committees in Utah and Tennessee about the potential impact of evidence-based standards on benefits for enrollees. Most recently, he was featured by CNN in a series of stories about the Michael Moore documentary “Sicko” critical of the health industry. Dr. Keckley received a B.A. from Lipscomb University, his MA/PhD from Ohio State University, and completed a fellowship in economic policy at Oxford University.




Alberto Gutierrez
Deputy Director for New Product Evaluation
FDA

Alberto Gutierrez, Ph.D., is the Deputy Director for New Product Evaluation in FDA’s Office of In Vitro Diagnostic Device Evaluation and Safety.  Dr. Gutierrez received a bachelor’s degree from Haverford College, and master and doctorate degrees in Chemistry from Princeton University.  Dr.Gutierrez has over 10 years of experience in research in the area of structural organic and organometallic chemistry.  Dr. Gutierrez joined the FDA in 1992 as researcher and reviewer in FDA’s Center for Biologics Evaluation and Research working on vaccine adjuvants and method development for determination of purity and structure of vaccine components.  In 2000, he joined the Office of In Vitro Diagnostic Device Evaluation and Safety as a scientific reviewer, becoming a Team leader for Toxicology in 2003, Director of the Division of Chemistry and Toxicology Devices in 2005 and Deputy Director of the Office of In Vitro Diagnostic Devices in 2007.



Mohan Iyer
Managing Director
Burrill & Company

One Embarcadero Center
Suite 2700
San Francisco, CA 94111
(415) 591-5400
www.burrillandco.com

Mr. Iyer brings to Burrill & Company a broad background in a range of functions including business development, strategic planning, marketing, product development, engineering and manufacturing. Prior to joining Burrill & Company, he was Executive VP of Corporate Development at diaDexus where he was responsible for sourcing and executing various types of transactions for a seven-year period, including discovery collaborations, in-licensing, out-licensing, manufacturing/supply contracts, and a spin-out. He has extensive experience in diagnostics, including alliances with major national reference laboratories. He also sourced and closed a therapeutic monoclonal antibody co-development agreement with Medarex. While at diaDexus, Mr. Iyer played a key role in two private financings totaling over $130mm, managed R&D operations for a transition year, and headed the marketing launch of a novel cardiovascular diagnostic product. Prior to diaDexus, he was a healthcare consultant at The Wilkerson Group where he managed several strategic engagements across the pharmaceutical, biotech, diagnostics and medical device industries. Mr. Iyer began his biotech career as a biochemical process engineer at Genentech, where he spent 7 years in positions ranging from biopharmaceutical manufacturing to capital projects management. He holds a BS in Chemical Engineering (Tennessee), an MS in Biomedical Engineering (Duke), and an MBA (Yale).




Ann Hanham
Managing Director
Burrill & Company

One Embarcadero Center
Suite 2700
San Francisco, CA 94111
(415) 591-5400
www.burrillandco.com

Prior to joining Burrill & Company, Ann Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune Pharmaceuticals, and prior to that, the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and the Medical Director for Celtrix Pharmaceuticals. She has also worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada.

Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986. She currently is a member of the Board of Directors of Adlyfe, Elbion, Endocyte, Logical Therapeutics, and Neosil.




Garrett Vygantas, M.D.
Senior Associate
Burrill & Company

One Embarcadero Center
Suite 2700
San Francisco, CA 94111
(415) 591-5400
www.burrillandco.com

Dr. Garrett Vygantas joined Burrill & Company in July of 2006 as a Senior Associate in the Venture Group and is involved in the sourcing, evaluating and structuring new investment opportunities across the life science spectrum. Dr. Vygantas is also a member of the Burrill International Group. He recently co-founded and is the interim CEO of NewBridge Pharmaceuticals, a Dubai-based specialty pharmaceutical company commercializing innovative therapies to treat chronic diseases of increasing incidence (diabetes, obesity, cardiovascular and cancer) and aesthetics in the Middle East, Africa, Turkey and Caspian regions. Before joining Burrill, Dr. Vygantas was with Genentech’s Market Planning Group where he focused on the commercialization and launch of Lucentis for the treatment of wet age-related macular degeneration. Prior to Genentech, Dr. Vygantas worked with retinal specialists in Chicago where he consulted on a variety of diabetes-related ophthalmic imaging projects.

Garrett previously worked at Cowen (Healthcare Investment Banking Group), and EntreMed (Business Development). Garrett serves on the Board of Directors of NewBridge and is a Board Observer on Nora Therapeutics, TRF Pharma, Proventys, and Efficas. He is a Co-Instructor at UCSF’s Center for BioEntrepreneurship’s “Idea to IPO” curriculum and has advised in the formation of numerous start-up biotech companies. Dr. Vygantas completed his Transitional Residency at the University of Pennsylvania and holds MD & MBA degrees from Georgetown University, as well as a B.S. in Biochemistry from Boston College.

Garrett is a member of the Kauffman Fellows Program.




Timothy Thompson
President & CEO
Proventys

2200 West Main Street, Suite 520
Durham, NC 27705
(919) 321-2783
www.proventys.com

Timothy Thompson is an accomplished healthcare executive with a proven track record of building and leading high performance organizations at early stage and Fortune 100 companies.

Prior to assuming the role of President and Chief Executive Officer of Proventys, Mr. Thompson was Managing Director of Business Development (Mergers & Acquisitions) at Aetna, Inc.  Mr. Thompson joined Aetna in 2002 to lead the formation of a new informatics business, Aetna Health Information Solutions, which was focused on monetizing the Company’s data assets and analytic capabilities.  There he built the organization from the ground up and led the development and successful commercialization of its market-leading, patient-centric database and analytic services.

Mr. Thompson has also served as Chief Operating Officer and Vice President of Business Development for PHT Corporation, an early stage, venture-backed mobile data capture and clinical trial software company. He joined PHT after successfully negotiating the company’s acquisition of Clinical Data Solutions, Inc. where he had been founder and CEO. At PHT, he oversaw all functional areas and led the organization through a period of rapid growth, commercializing its market-leading mobile data capture solution domestically and internationally.

Mr. Thompson received a BA in Zoology and Biochemistry from the University of New Hampshire where he was elected into the Phi Beta Kappa honor society.